Interesting read, page-6

There are quite a few articles that are appropriate.
http://www.thepharmaletter.com/arti...nd-gigantism-treatment-limiting-market-growth
Initially this article said that ATL1103 is as good as Somavert, it did go on to say
that ATL1103 may struggle to make an impact as physicians will be weary of replacing somavert with ATL1103.
These new treatment will only attract a small subset of the market as they are not effective as current standard of care therapies.
Positives here, off current phII data ATL1103 will definitely rival Somavert, we just need to prove our product to the people that will recommend us to patients. It appears from everything we know ATL1103 looks to be the front runner to rival somavert, if this high dose trial goes well it may eventuate that ATL1103 could be the most effective treatment for acromegaly in the world as it appears there aren't many other pharma's out there with anything to compete with.
The market for acromegaly is estimated to be $707 million by 2018.  Knowing that ATL1103 is looking to be as effective as Somavert, requires less frequent dosage and may be significantly cheaper, I can only assume ANP will take a decent percentage of this market if all goes according to plan. ANP's MC of $15 million, this is just one of the many reasons I see ANP as an attractive buy.